Ventyx Biosciences Inc
VTYX9.260USD
+0.080+0.87%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
660.58MMarket Cap
LossP/E TTM
More Details of Ventyx Biosciences Inc Company
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Ventyx Biosciences Inc Info
Ticker SymbolVTYX
Company nameVentyx Biosciences Inc
IPO dateOct 21, 2021
CEOMohan (Raju)
Number of employees79
Security typeOrdinary Share
Fiscal year-endOct 21
Address12790 El Camino Real, Suite 200
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone17604076511
Websitehttps://ventyxbio.com/
Ticker SymbolVTYX
IPO dateOct 21, 2021
CEOMohan (Raju)
Company Executives of Ventyx Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.30M
--
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Roy M. Gonzales
Mr. Roy M. Gonzales
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. William R. White, J.D.
Mr. William R. White, J.D.
Independent Director
Independent Director
--
--
Ms. Onaiza Cadoret - Manier
Ms. Onaiza Cadoret - Manier
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Moore
Mr. Matthew (Matt) Moore
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.30M
--
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 15
Updated: Mon, Dec 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Science Ventures, LLC
5.65%
Affinity Asset Advisors LLC
5.50%
The Vanguard Group, Inc.
5.28%
Point72 Asset Management, L.P.
4.50%
Tang Capital Management, LLC
4.34%
Other
74.72%
Shareholders
Shareholders
Proportion
New Science Ventures, LLC
5.65%
Affinity Asset Advisors LLC
5.50%
The Vanguard Group, Inc.
5.28%
Point72 Asset Management, L.P.
4.50%
Tang Capital Management, LLC
4.34%
Other
74.72%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.48%
Investment Advisor/Hedge Fund
15.42%
Investment Advisor
13.94%
Venture Capital
5.93%
Individual Investor
4.24%
Research Firm
3.57%
Family Office
0.10%
Other
27.31%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
354
49.84M
69.85%
-50.63M
2025Q2
368
54.53M
76.62%
-50.77M
2025Q1
385
51.70M
72.65%
-54.51M
2024Q4
397
65.14M
91.63%
-35.16M
2024Q3
387
62.43M
88.32%
-37.01M
2024Q2
376
67.39M
95.54%
-30.30M
2024Q1
369
70.49M
100.19%
-8.56M
2023Q4
345
54.61M
92.50%
-19.94M
2023Q3
315
66.31M
112.60%
-5.18M
2023Q2
302
65.66M
112.13%
-3.35M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Science Ventures, LLC
4.03M
5.65%
-3.07M
-43.23%
Mar 28, 2025
Affinity Asset Advisors LLC
4.54M
6.36%
+479.08K
+11.81%
Jun 30, 2025
The Vanguard Group, Inc.
3.16M
4.43%
-350.93K
-9.99%
Jun 30, 2025
Point72 Asset Management, L.P.
5.90M
8.27%
+1.66M
+39.21%
Jun 30, 2025
Tang Capital Management, LLC
3.10M
4.35%
--
--
Jun 30, 2025
Mohan (Raju)
2.30M
3.23%
--
--
Apr 10, 2025
Marshall Wace LLP
2.40M
3.36%
+2.40M
--
Jun 30, 2025
Vestal Point Capital, LP
2.00M
2.8%
--
--
Jun 30, 2025
Citadel Advisors LLC
1.77M
2.48%
+372.14K
+26.71%
Jun 30, 2025
Millennium Management LLC
1.41M
1.97%
+1.18M
+521.16%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
1.91%
iShares Health Innovation Active ETF
0.29%
iShares Micro-Cap ETF
0.11%
Avantis US Small Cap Equity ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion1.91%
iShares Health Innovation Active ETF
Proportion0.29%
iShares Micro-Cap ETF
Proportion0.11%
Avantis US Small Cap Equity ETF
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Schwab U.S. Small-Cap ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ventyx Biosciences Inc?
The top five shareholders of Ventyx Biosciences Inc are:
New Science Ventures, LLC holds 4.03M shares, accounting for 5.65% of the total shares.
Affinity Asset Advisors LLC holds 4.54M shares, accounting for 6.36% of the total shares.
The Vanguard Group, Inc. holds 3.16M shares, accounting for 4.43% of the total shares.
Point72 Asset Management, L.P. holds 5.90M shares, accounting for 8.27% of the total shares.
Tang Capital Management, LLC holds 3.10M shares, accounting for 4.35% of the total shares.
New Science Ventures, LLC holds 4.03M shares, accounting for 5.65% of the total shares.
Affinity Asset Advisors LLC holds 4.54M shares, accounting for 6.36% of the total shares.
The Vanguard Group, Inc. holds 3.16M shares, accounting for 4.43% of the total shares.
Point72 Asset Management, L.P. holds 5.90M shares, accounting for 8.27% of the total shares.
Tang Capital Management, LLC holds 3.10M shares, accounting for 4.35% of the total shares.
What are the top three shareholder types of Ventyx Biosciences Inc?
The top three shareholder types of Ventyx Biosciences Inc are:
New Science Ventures, LLC
Affinity Asset Advisors LLC
The Vanguard Group, Inc.
New Science Ventures, LLC
Affinity Asset Advisors LLC
The Vanguard Group, Inc.
How many institutions hold shares of Ventyx Biosciences Inc (VTYX)?
As of 2025Q3, 354 institutions hold shares of Ventyx Biosciences Inc, with a combined market value of approximately 49.84M, accounting for 69.85% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -6.77%.
What is the biggest source of revenue for Ventyx Biosciences Inc?
In --, the -- business generated the highest revenue for Ventyx Biosciences Inc, amounting to -- and accounting for --% of total revenue.
